文献速递胃肠外科肝胆胰外科围术期管理与 ERAS

术前高剂量糖皮质激素在消化系统肿瘤手术中的随机临床试验

Preoperative High-Dose Corticosteroids in Digestive Cancer Surgery: A Randomized Clinical Trial.
PubMed 文献 · JAMA Surg · 2026-01-01

这项双盲、安慰剂对照、优效性随机临床试验在23家法国医院纳入1210例择期根治性消化系统肿瘤手术患者,比较术前静脉甲泼尼龙20 mg/kg与安慰剂。结论认为术前脉冲式糖皮质激素对术后结局无获益,不推荐常规使用。

要点

  • 术后感染、腹腔感染、伤口愈合不良及住院时间两组均无显著差异。
  • 不推荐在择期消化系统肿瘤手术中常规使用术前脉冲式糖皮质激素。

核心结论

  • 术前脉冲剂量糖皮质激素对择期消化系统肿瘤手术的术后结局无获益,不应推荐常规使用。

研究设计与样本

  • 双盲、安慰剂对照、优效性随机临床试验,在23家法国医院开展,2019至2023年纳入1210例择期根治性消化系统肿瘤手术患者。
  • 干预为麻醉时静脉甲泼尼龙20 mg/kg或外观相同的安慰剂;排除仅行肝脏手术且无消化道吻合的患者。
  • 主要终点为术后30天内主要术后并发症;共1188例完成30天随访(每组594例)。

临床怎么用

  • 择期消化系统肿瘤手术不应常规给予术前高剂量糖皮质激素以预防术后并发症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Modulating perioperative inflammation could be associated with fewer postoperative complications and better outcomes in major digestive surgery. The clinical benefit of corticosteroids with this purpose remains controversial. OBJECTIVE: To assess whether preoperative high-dose corticosteroids improve postoperative outcomes after surgery for digestive cancer. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, placebo-controlled, superiority randomized clinical trial included patients undergoing elective surgery with curative intent for digestive cancer. This was a multicenter trial with the participation of 23 French hospitals working as a reference for digestive surgical oncology. Among patients referred for major digestive surgery to the participating centers, those undergoing surgery for digestive cancer with a curative intent between 2019 and 2023 were randomized. Patients undergoing only hepatic surgery without digestive anastomosis were excluded. INTERVENTIONS: Patients included were randomized to receive either 20 mg/kg of intravenous methylprednisolone at the time of anesthesia or a placebo with an identical aspect. MAIN OUTCOMES AND MEASURES: The primary end point was the onset of major postoperative complications within 30 days after surgery. Secondary end points were postoperative infections, intra-abdominal infections, wound infections, unsatisfactory wound healing within 30 days after surgery, and the length of hospital stay after surgery. RESULTS: Among 2461 patients referred for major digestive surgery, 1210 patients (mean [SD] age, 65.9 [11.3] years; 762 male [63%]) undergoing surgery for digestive cancer were randomized. Among the 1188 patients with follow-up at postoperative day 30 (594 per arm), major postoperative complications did not significantly differ between the 2 groups (139 of 594 [23%] receiving methylprednisolone vs 119 of 594 [20%] receiving placebo; P = .16). Secondary outcomes did not differ either between the group receiving methylprednisolone and the group receiving placebo (postoperative infections: 182 of 594 [31%] vs 177 of 594 [30%]; P = .75; intra-abdominal infections: 142 of 594 [24%] vs 126 of 594 [21%]; P = .27; unsatisfactory wound healing: 87 of 594 [15%] vs 69 of 594 [12%]; P = .13; mean [SD] length of hospital stay: 13.21 [8.59] days vs 12.97 [8.1] days; P = .93). CONCLUSIONS AND RELEVANCE: A preoperative pulse dose of corticosteroids had no benefit on postoperative outcomes in elective digestive cancer surgery and should not be recommended in routine practice. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03875690.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Ortega-Deballon P, Bourredjem A, Régimbeau JM, et al. Preoperative High-Dose Corticosteroids in Digestive Cancer Surgery: A Randomized Clinical Trial. JAMA Surg. 2026. PMID: 42616512. doi:10.1001/jamasurg.2026.3557

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。